Faculty

Institution

Unit

Venue

George L. Chen

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Stem Cell Transplantation

The University of Texas MD Anderson Cancer Center

NoneGeorge L. Chen is currently serving as a Breast Surgical Oncology faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

George L. Chen

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

hematology medicine immunology clinical transplantation cell transplantation transplantation medicine bone marrow transplantation organ transplantation stem cell transplantation oncology pharmacology cellular therapy regenerative medicine cell therapy graft survival dermatology clinical research medicinal research transplant infectious diseases immunotherapy clinical immunology cancer immunotherapy clinical trials liver transplantation experimental medicine graft rejection pharmacotherapy leukemia cancer treatment myeloid neoplasia chronic graft-versus-host disease hematopoietic cell transplantation laboratory medicine transplantation proceeding stem-cell therapy hematological malignancies medical virology hemostasis cutaneous sclerosis anti-cancer agents lymphoid neoplasia transplant surgery overall survival oncogenes cohort studies radiation biology older patients chronic gvhd consortium thrombosis molecular cancer therapeutic efficacy clinical evidence tissue transplantation bone marrow failure novel therapies tumor targeting cancer genetics blood transfusion allogeneic transplantation successful engraftment study protocol immune dysregulation patient experience immunohaematology systemic therapy biological therapies t-regulatory cell cellular immune responses adaptive immune system late acute chronic gvhd updated analysis nonrelapse mortality prophylactic rituximab b-cell alloimmunity prospective analysis

Notable Scholarly Works

Notable Federal Grants

Collaborators

Administration of Off-The-Shelf, Expanded, Most Closely Hla Matched, Third Party Viral Specific T Cells for the Therapy of Adenovirus Related Disease in Adult Immunocompromised Patients. Transplantation and Cellular Therapy (2026)

infectious diseasesvirologycell therapyantiviral responsesimmunologyimmunotherapycellular therapyantiviral therapyadenovirus related diseaseimmunity (medicine)medicinemedical virology

Adverse Impact of Mmf in Aml/Mds Patients With High Hct-CI Receiving Matched Allogeneic Stem Cell Transplantation With Ptcy-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy (2026)

ptcy-based gvhd prophylaxiscell therapygraft rejectionimmunologycell transplantationstem cellshematologybone marrow transplantationadverse impactmedicinestem cell transplantationleukemiaaml/mds patients

A Phase 2 Trial of Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk Mds. Transplantation and Cellular Therapy (2026)

myeloablative fractionated busulfanclinical therapeuticshigh-risk mdsapplied pharmacologymetronomic chemotherapyphase 2medicinepharmacologyclinical pharmacologyclinical researchpharmacotherapyclinical trialsoncology

A Phase II Open-Label Study of Olutasidenib Post-Transplant Maintenance Therapy for Patients With Idh1-Mutated Myeloid Malignancies. Transplantation and Cellular Therapy (2026)

cell replacement therapiesradiation oncologyidh1-mutated myeloid malignanciescell transplantationhematologymedicineclinical transplantationstem cell transplantationoncologymyeloid neoplasia

Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-host Disease. JAMA Dermatology (2026)

transplant infectious diseasespsoriasisorgan transplantationtransplantation proceedingrheumatologywound healingsurgerydermatologydermatological treatmentsclerodermabone marrow transplantationoutcomes researchmedicineclinical transplantationautoimmune diseasesclinical rheumatologycosmetic dermatology

Evaluate the Safety and Efficacy of Short Versus Long Infusion Schedules of Evomela as Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma.Interpret Bayesian Modeling Results Assessing the Relationship Between Melphalan Exposure (Auc) and Depth of Response or Progression-Free Survival.Identify Potential Pharmacokinetic (Auc) Targets That May Guide Individualized Evomela Dosing Strategies, Particularly for Patients With High-Risk Cytogenetics. Transplantation and Cellular Therapy (2026)

radiation oncologyhigh-risk cytogeneticscell therapymelphalan exposurecell transplantationhematological malignancieshematologybone marrow transplantationcancer researchmedicineclinical transplantationexperimental medicinestem cell transplantationoncology

Incidence of Cytomegalovirus Infections After Standard of Care Cd19 Car-T Cell Therapy: A Retrospective Analysis.. Transplantation and Cellular Therapy (2026)

infectious diseasescell therapyimmunologycell transplantationimmunotherapycellular therapyinfectious diseases (medical specialty)medicinemedical virology

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant. American Journal of Hematology (2026)

Mmf Use is Associated With Increased Early Infections in Aml/Mds Patients Undergoing Allogeneic Transplant With Ptcy-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy (2026)

transplant infectious diseasesptcy-based gvhd prophylaxisorgan transplantationgraft rejectionimmunologycell transplantationhematologybone marrow transplantationhospital infectionsmedicineclinical transplantationstem cell transplantationearly infectionsgraft survivalmmf use

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk Aml: A Phase 2 Trial. Transplantation and Cellular Therapy (2026)

myeloablative fractionated busulfanapplied pharmacologyhigh-risk amlhematological malignancieshematologyphase 2medicinepharmacologyexperimental medicineclinical researchpharmacotherapyleukemiaclinical trialsclinical pharmacologymyeloid neoplasia

1
2
3
4
5
14
10 / page

George L. Chen

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Stem Cell Transplantation

The University of Texas MD Anderson Cancer Center

NoneGeorge L. Chen is currently serving as a Breast Surgical Oncology faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

George L. Chen

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

infectious diseasesvirologycell therapyantiviral responsesimmunologyimmunotherapycellular therapyantiviral therapyadenovirus related diseaseimmunity (medicine)medicinemedical virology

Adverse Impact of Mmf in Aml/Mds Patients With High Hct-CI Receiving Matched Allogeneic Stem Cell Transplantation With Ptcy-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy (2026)

A Phase 2 Trial of Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk Mds. Transplantation and Cellular Therapy (2026)

A Phase II Open-Label Study of Olutasidenib Post-Transplant Maintenance Therapy for Patients With Idh1-Mutated Myeloid Malignancies. Transplantation and Cellular Therapy (2026)

cell replacement therapiesradiation oncologyidh1-mutated myeloid malignanciescell transplantationhematologymedicineclinical transplantationstem cell transplantationoncologymyeloid neoplasia

Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-host Disease. JAMA Dermatology (2026)

Incidence of Cytomegalovirus Infections After Standard of Care Cd19 Car-T Cell Therapy: A Retrospective Analysis.. Transplantation and Cellular Therapy (2026)

infectious diseasescell therapyimmunologycell transplantationimmunotherapycellular therapyinfectious diseases (medical specialty)medicinemedical virology

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant. American Journal of Hematology (2026)

Mmf Use is Associated With Increased Early Infections in Aml/Mds Patients Undergoing Allogeneic Transplant With Ptcy-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy (2026)

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk Aml: A Phase 2 Trial. Transplantation and Cellular Therapy (2026)

1
2
3
4
5
14
10 / page